• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

    4.450 -0.170 (-3.68%)
    Streaming Delayed Price Updated: 10:48 AM EST, Jan 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 336,640
    Open 4.590
    Bid (Size) 4.440 (1,400)
    Ask (Size) 4.450 (1,200)
    Prev. Close 4.620
    Today's Range 4.420 - 4.590
    52wk Range 2.705 - 5.100
    Shares Outstanding 99,161,234
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
    Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
    Via PredictStreet
    Topics Initial Public Offering Intellectual Property
    News headline image
    Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire

    Performance

    YTD
    -6.7%
    -6.7%
    1 Month
    -5.5%
    -5.5%
    3 Month
    +4.0%
    +4.0%
    6 Month
    +37.3%
    +37.3%
    1 Year
    +32.8%
    +32.8%

    More News

    Read More
    News headline image
    Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗
    Via Chartmill
    News headline image
    Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus (ABUS) Q2 Revenue Surges 529% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Provides 2025 Corporate and Financial Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
    From Whitefort Capital Management, LP
    Via Business Wire
    News headline image
    Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
    Via Benzinga
    News headline image
    Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    News headline image
    Arbutus to Present at Jefferies London Healthcare Conference
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine ↗
    Via Benzinga
    Topics Intellectual Property
    News headline image
    Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
    From Arbutus Biopharma Corporation
    Via GlobeNewswire

    Frequently Asked Questions

    Is Arbutus Biopharma Corporation - Common Stock publicly traded?
    Yes, Arbutus Biopharma Corporation - Common Stock is publicly traded.
    What exchange does Arbutus Biopharma Corporation - Common Stock trade on?
    Arbutus Biopharma Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arbutus Biopharma Corporation - Common Stock?
    The ticker symbol for Arbutus Biopharma Corporation - Common Stock is ABUS on the Nasdaq Stock Market
    What is the current price of Arbutus Biopharma Corporation - Common Stock?
    The current price of Arbutus Biopharma Corporation - Common Stock is 4.450
    When was Arbutus Biopharma Corporation - Common Stock last traded?
    The last trade of Arbutus Biopharma Corporation - Common Stock was at 01/12/26 10:48 AM ET
    What is the market capitalization of Arbutus Biopharma Corporation - Common Stock?
    The market capitalization of Arbutus Biopharma Corporation - Common Stock is 441.27M
    How many shares of Arbutus Biopharma Corporation - Common Stock are outstanding?
    Arbutus Biopharma Corporation - Common Stock has 441M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.